跳至主要内容
临床试验/JPRN-jRCT1080224937
JPRN-jRCT1080224937已完成Unknown

The special drug use surveillance of INAVIR for inhalation suspension set (Safety evaluation in pediatric patients under five years old)

DAIICHI SANKYO CO., LTD.0 个研究点目标入组 1,156 人开始时间: 2019年11月6日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
入组人数
1,156

研究概览

简要总结

The results of this surveillance verified that there are no noticeable problems with the safety or efficacy of laninamivir for children under the age of 5 infected with the influenza A and B viruses.

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 <= 4age old(—)
性别
All

入选标准

  • 1) Patients had not been treated with INAVIR for inhalation suspension set in the same influenza season.
  • 2) Children under five years old
  • 3) Patients had been diagnosed by a participating physician as being influenza virus infection positive based on a rapid diagnosis kit.
  • 4) Patients were not suspected of primary or secondary infection with pathogenic microorganisms(viruses/bacteria)other than the influenza virus.
  • 5) Patients obtained written informed consent from their guardians.

排除标准

  • 未提供

研究者

相似试验